ASX Announcement **27 August 2021**

Atomo FY21 results investor briefing

SYDNEY Australia Friday, 27 August 2021: Atomo Diagnostics Limited (ASX: AT1) is pleased to invite investors to attend an online briefing to discuss its financial results for the year ended 30 June 2021 (FY21).

The online briefing will be held on **Monday, 30 August 2021** at **2.30pm (Sydney time)**.

During the briefing, Managing Director and CEO, John Kelly and CFO, Will Souter will present an activity update. This will be followed by a Q+A session.

Participants will need to pre-register ahead of time, via the following link:

https://us02web.zoom.us/webinar/register/WN_xp5x0SdjQP2ToylcRAhb2g

Once the registration form is completed, investors will receive a confirmation email with detail on how to access the briefing. If you would like to ask a question during the briefing, please send it ahead of the session to: george.kopsiaftis@irdepartment.com.au

For more information, please contact:

Jane Lowe
IR Department
jane.lowe@irdepartment.com.au
Phone: +61 411 117 774

John Kelly
Atomo Diagnostics
john.kelly@atomodiagnostics.com
Phone: +61 401 922 279

This announcement was authorised by John Kelly, Managing Director.

About Atomo

Atomo is an Australian medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market. Atomo's patented devices simplify testing procedures and enhance usability for professional users and untrained self-testers. Atomo has supply agreements in place for tests targeting a range of infectious diseases including for HIV, COVID-19, and viral vs bacterial differentiation.

See more at www.atomodiagnostics.com.